Phase III Studies and Guideline Recommendations*
* In Hong Kong, TS-ONE ® is indicated for post operative adjuvant chemotherapy for locally advanced (stage II (excluding T1), IIIA or IIIB) gastric cancer
Colorectal Cancer
- Cervantes A. et al., 2023. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Jan;34(1), pp. 10-32.
- Hashiguchi Y. et al., 2020. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.
Int J Clin Oncol., 25(1), pp.1-42. - Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic colorectal cancer 2018.
- Yamada Y. et al., 2018. S-1 and Irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Ann Oncol., 29(3), pp.624-631. - Kwakman JJM. et al., 2017. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
Ann Oncol., 28(6), pp.1288-1293. - Yoshida M. et al., 2014. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial).
Ann Oncol., 25(9), pp 1743-1749. - Young Sang Hong et al., 2012. S-1 plus oxaliplatin verses capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Lancet Oncol., 13, pp.1125-1132. - Yamada Y. et al., 2013. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority randomised phase 3 trial.
Lancet Oncol., 14(13), pp.1278-86. - Muro K. et al., 2010. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomized phase 2/3 non-inferiority study (FIRIS study)
Lancet Oncol., 11, pp.853-860.
This Site is intended for Hong Kong healthcare professionals only. Products discussed herein may have different labeling in different countries. TS-ONE® is a registered trademark of TAIHO PHARMACEUTICAL CO., LTD. and used under license. Copyright © TAIHO PHARMACEUTICAL CO., LTD. 2020 All rights reserved.